Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer - Abstract

PURPOSE:Local progression, in patients with hormone-refractory prostate cancer, often causes significant morbidity.

Pelvic radiotherapy (RT) provides effective palliation in this setting, with most published studies supporting the use of high-dose regimens. The aim of the present study was to examine the role of split-course hypofractionated RT used at our institution in treating this group of patients.

METHODS AND MATERIALS: A total of 34 men with locoregionally progressive hormone-refractory prostate cancer, treated with a split course of pelvic RT (45-60 Gy in 18-24 fractions) between 2000 and 2008 were analyzed. The primary endpoints were the response rate and actuarial locoregional progression-free survival. Secondary endpoints included overall survival, compliance, and acute and late toxicity.

RESULTS: The median age was 71 years (range, 53-88). Treatment resulted in an overall initial response rate of 91%, a median locoregional progression-free survival of 43 months, and median overall survival of 28 months. Compliance was excellent and no significant late toxicity was reported.

CONCLUSIONS: The split course pelvic RT described has an acceptable toxicity profile, is effective, and compares well with other high-dose palliative regimens that have been previously reported.

Written by:
Gogna NK, Baxi S, Hickey B, Baumann K, Burmeister E, Holt T. Are you the author?
Radiation Oncology Services, Mater Centre, Brisbane, Queensland, Australia.

Reference: Int J Radiat Oncol Biol Phys. 2012 Feb 16. Epub ahead of print.
doi: 10.1016/j.ijrobp.2011.12.028

PubMed Abstract
PMID: 22342096